These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 22081263)

  • 21. A randomized, open-label, multicenter trial of immediate versus delayed intervention with darbepoetin alfa for chemotherapy-induced anemia.
    Charu V; Saidman B; Ben-Jacob A; Justice GR; Maniam AS; Tomita D; Rossi G; Rearden T; Glaspy J
    Oncologist; 2007 Oct; 12(10):1253-63. PubMed ID: 17962619
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Darbepoetin alfa administered once every three weeks for the treatment of anemia in elderly patients with non-myeloid tumors receiving chemotherapy.
    Esquerdo G; Doménech M; López P; Pedro C; Villadiego K; Constenla M; Sánchez-Rovira P; Gasquet JA; Rodríguez CA;
    Tumori; 2014; 100(2):225-31. PubMed ID: 24852870
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment of chemotherapy-induced anemia in breast cancer: results of a randomized controlled trial of darbepoetin alfa 200 microg every 2 weeks versus epoetin alfa 40,000 U weekly.
    Senecal FM; Yee L; Gabrail N; Charu V; Tomita D; Rossi G; Schwartzberg L
    Clin Breast Cancer; 2005 Dec; 6(5):446-54. PubMed ID: 16381629
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase III, randomized study of the effects of parenteral iron, oral iron, or no iron supplementation on the erythropoietic response to darbepoetin alfa for patients with chemotherapy-associated anemia.
    Steensma DP; Sloan JA; Dakhil SR; Dalton R; Kahanic SP; Prager DJ; Stella PJ; Rowland KM; Novotny PJ; Loprinzi CL
    J Clin Oncol; 2011 Jan; 29(1):97-105. PubMed ID: 21098317
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hemoglobin stability in patients with anemia, CKD, and type 2 diabetes: an analysis of the TREAT (Trial to Reduce Cardiovascular Events With Aranesp Therapy) placebo arm.
    Skali H; Lin J; Pfeffer MA; Chen CY; Cooper ME; McMurray JJ; Nissenson AR; Remuzzi G; Rossert J; Parfrey PS; Scott-Douglas NW; Singh AK; Toto R; Uno H; Ivanovich P
    Am J Kidney Dis; 2013 Feb; 61(2):238-46. PubMed ID: 23159232
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An extended maintenance dosing regimen of epoetin alfa 80,000 U every 3 weeks in anemic patients with cancer receiving chemotherapy.
    Montoya VP; Xie J; Williams D; Woodman RC; Wilhelm FE
    Support Care Cancer; 2007 Dec; 15(12):1385-92. PubMed ID: 17541653
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Oral sucrosomial iron versus intravenous iron in anemic cancer patients without iron deficiency receiving darbepoetin alfa: a pilot study.
    Mafodda A; Giuffrida D; Prestifilippo A; Azzarello D; Giannicola R; Mare M; Maisano R
    Support Care Cancer; 2017 Sep; 25(9):2779-2786. PubMed ID: 28391437
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hemoglobin level at initiation of darbepoetin alfa: impact on need for transfusion and associated costs in chemotherapy-induced anemia treatment in Europe.
    Deger M; Eisterer W; Kutikova L; Salek S
    Support Care Cancer; 2013 Feb; 21(2):485-93. PubMed ID: 22825456
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A prospective cohort study on the impact of darbepoetin alfa on quality of life in daily practice following anemia treatment guideline revisions.
    Steinmetz T; Kindler M; Lange O; Vehling-Kaiser U; Kuhn A; Hellebrand E
    Curr Med Res Opin; 2014 Sep; 30(9):1813-20. PubMed ID: 24849527
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Correlation between variation in quality of life and change in hemoglobin level after treatment with epoetin alfa 40,000 IU administered once-weekly.
    Cartenì G; Giannetta L; Ucci G; De Signoribus G; Vecchione A; Pinotti G; Puglisi F; Contillo A; Pezzella G; Orecchia S; Beccaglia P;
    Support Care Cancer; 2007 Sep; 15(9):1057-66. PubMed ID: 17431689
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treating anemia of cancer with every-4-week darbepoetin alfa: final efficacy and safety results from a phase II, randomized, double-blind, placebo-controlled study.
    Gordon D; Nichols G; Ben-Jacob A; Tomita D; Lillie T; Miller C
    Oncologist; 2008 Jun; 13(6):715-24. PubMed ID: 18586927
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Randomized, dose-finding study of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies.
    Hedenus M; Hansen S; Taylor K; Arthur C; Emmerich B; Dewey C; Watson D; Rossi G; Osterborg A;
    Br J Haematol; 2002 Oct; 119(1):79-86. PubMed ID: 12358906
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A randomized, controlled trial comparing darbepoetin alfa correction/maintenance dosing with weekly dosing for treating chemotherapy-induced anemia.
    Kotasek D; Canon JL; Mateos MV; Hedenus M; Rossi G; Taylor K
    Curr Med Res Opin; 2007 Jun; 23(6):1387-401. PubMed ID: 17559735
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update.
    Rizzo JD; Somerfield MR; Hagerty KL; Seidenfeld J; Bohlius J; Bennett CL; Cella DF; Djulbegovic B; Goode MJ; Jakubowski AA; Rarick MU; Regan DH; Lichtin AE; ;
    J Clin Oncol; 2008 Jan; 26(1):132-49. PubMed ID: 17954713
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dose efficiency of erythropoiesis-stimulating agents for the treatment of patients with chemotherapy-induced anemia: a systematic review.
    Forbes CA; Worthy G; Harker J; Kleijnen J; Kutikova L; Zelek L; Van Belle S
    Clin Ther; 2014 Apr; 36(4):594-610. PubMed ID: 24656152
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Darbepoetin alfa administered every 4 weeks for anemia in patients with advanced prostate cancer.
    Beer TM; Bergenstock M; Birt K; Higano CS
    Clin Genitourin Cancer; 2007 Jun; 5(5):329-33. PubMed ID: 17645830
    [TBL] [Abstract][Full Text] [Related]  

  • 37. C.E.R.A. corrects anemia in patients with chronic kidney disease not on dialysis: results of a randomized clinical trial.
    Macdougall IC; Walker R; Provenzano R; de Alvaro F; Locay HR; Nader PC; Locatelli F; Dougherty FC; Beyer U;
    Clin J Am Soc Nephrol; 2008 Mar; 3(2):337-47. PubMed ID: 18287255
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An observational study of the effectiveness of darbepoetin alpha administered in dialysis patients once every 2 weeks for 12 months.
    Rottembourg JB; Bridges I; Pronai W; Feriani M; McMahon LP; De Meester JM; Farouk M; Molemans B
    Clin Nephrol; 2011 Mar; 75(3):242-50. PubMed ID: 21329635
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update.
    Rizzo JD; Somerfield MR; Hagerty KL; Seidenfeld J; Bohlius J; Bennett CL; Cella DF; Djulbegovic B; Goode MJ; Jakubowski AA; Rarick MU; Regan DH; Lichtin AE
    Blood; 2008 Jan; 111(1):25-41. PubMed ID: 17954703
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia: the 20030125 Study Group Trial.
    ; Glaspy J; Vadhan-Raj S; Patel R; Bosserman L; Hu E; Lloyd RE; Boccia RV; Tomita D; Rossi G
    J Clin Oncol; 2006 May; 24(15):2290-7. PubMed ID: 16710026
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.